Galmed Pharma Adds China Arm to Phase IIb Trial of Liver Disease Drug

Galmed Pharma of Israel has expanded its Phase IIb clinical trial of aramchol, a liver disease treatment, to include a China arm. At the same time, Galmed started a pharmacokinetic study of the drug in healthy China citizens who live in the US. Aramchol, a once-daily, oral drug, is aimed at treating non-alcoholic steatohepatitis (NASH). Originally, the ARREST study of aramchol was expected to enroll patients in 70 centers in 12 countries, including the United States. More details.... Stock Symbol: (NSDQ: GLMD) Share this with colleagues: // //